Sonia Gulati

Sonia Gulati, PhD is a Principal at Global BioAccess Fund, a New York-based venture capital firm focused on novel therapeutics and devices for serious unmet medical needs. The firm states that it funds companies needing capital to support IND submission and clinical trials, most often from Series A through Series C.

Before joining Global BioAccess Fund, Gulati was an Executive in Residence at Kairos Ventures, where she focused on venture creation. In that role, she drove investment processes and served as interim CEO for newly formed portfolio companies.

Earlier, Gulati was Assistant Director at New York Ventures, where she managed the life sciences portfolio. She previously worked at a boutique healthcare consultancy, helping biopharma clients shape product launch and life-cycle management strategies.

Gulati completed postdoctoral studies and earned her PhD from Columbia University’s Vagelos College of Physicians and Surgeons. She also holds a BA from Barnard College, Columbia University.

• Global BioAccess Fund invests in companies developing novel therapeutics and devices for serious unmet medical needs in oncology, I&I, rare disease, CNS, and cardiology.
• The firm’s stated investment focus: “We fund companies who need capital to support IND submission and clinical trials.”
• Global BioAccess Fund most often invests from Series A to Series C and can participate in crossover financings.
• The firm can lead, co-lead, or actively participate in financing rounds.
• Gulati’s operating angle is venture creation: at Kairos Ventures, she worked with founding scientists, drove investment processes, and acted as interim CEO for newly formed companies.
• In April 2025, discussing TigaTx’s merger with Epsilogen, Gulati said she believed in the potential of IgA and IgE-based therapies to transform cancer treatment.